Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Publication/Presentation Date
5-1-2020
Abstract
BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).
METHODS: CREDENCE randomly assigned 4401 participants with an eGFR of 30 to < 90 ml/min per 1.73 m
RESULTS: At screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to < 45, 45 to < 60, and 60 to < 90 ml/min per 1.73 m
CONCLUSIONS: Canagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to < 45 ml/min per 1.73 m
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.
Volume
31
Issue
5
First Page
1128
Last Page
1139
ISSN
1533-3450
Published In/Presented At
Jardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., Bajaj, H. S., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Di Tanna, G. L., Greene, T., Heerspink, H. J. L., Levin, A., Neal, B., Pollock, C., Qiu, R., Sun, T., Wheeler, D. C., … CREDENCE Study Investigators (2020). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology : JASN, 31(5), 1128–1139. https://doi.org/10.1681/ASN.2019111168
Disciplines
Medicine and Health Sciences
PubMedID
32354987
Department(s)
Department of Medicine
Document Type
Article